OPVEE

Asset

Stage
Approved
Modality
Not known
Target
Not known
1
Indication
0
Trials
1
Developer

Approved by the FDA on May 22, 2023 (NDA217470). FDA

Indications

1
  • No named disease

    Approved, FDA, May 22, 2023

In the full profile

  • Owner and partners1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets